KR101072897B1 - COMPOSITION FOR ALLEVIATING A HANGOVER COMPRISING AN EXTRACT OF Trapa japonica Flerov - Google Patents
COMPOSITION FOR ALLEVIATING A HANGOVER COMPRISING AN EXTRACT OF Trapa japonica Flerov Download PDFInfo
- Publication number
- KR101072897B1 KR101072897B1 KR1020080135697A KR20080135697A KR101072897B1 KR 101072897 B1 KR101072897 B1 KR 101072897B1 KR 1020080135697 A KR1020080135697 A KR 1020080135697A KR 20080135697 A KR20080135697 A KR 20080135697A KR 101072897 B1 KR101072897 B1 KR 101072897B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- hangover
- composition
- dried
- earth
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 206010019133 Hangover Diseases 0.000 title claims abstract description 49
- 239000000284 extract Substances 0.000 title claims abstract description 49
- 241001428357 Trapa japonica Species 0.000 title description 2
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 11
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 15
- 235000013372 meat Nutrition 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 5
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims 2
- 229910052733 gallium Inorganic materials 0.000 claims 2
- 241001233061 earthworms Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 57
- 230000001737 promoting effect Effects 0.000 abstract description 35
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 abstract description 28
- 235000013305 food Nutrition 0.000 abstract description 18
- 235000013361 beverage Nutrition 0.000 abstract description 13
- 239000012676 herbal extract Substances 0.000 abstract description 13
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 abstract description 3
- 125000003158 alcohol group Chemical group 0.000 abstract description 3
- 238000000354 decomposition reaction Methods 0.000 abstract description 3
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 27
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 24
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 24
- 238000012360 testing method Methods 0.000 description 19
- 230000036541 health Effects 0.000 description 12
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 230000009931 harmful effect Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 238000011990 functional testing Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 108010033145 microsomal ethanol-oxidizing system Proteins 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- -1 pH adjusters Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 244000307700 Fragaria vesca Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 244000010000 Hovenia dulcis Species 0.000 description 1
- 235000008584 Hovenia dulcis Nutrition 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000005415 artificial ingredient Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 231100000149 liver necrosis Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 생약 혼합 추출물을 함유하는 숙취해소용 조성물에 관한 것으로, 마름, 연자육 및 지구자의 추출물 또는 마름, 연자육, 지구자 및 갈화의 추출물을 유효성분으로 함유하는 본 발명의 숙취해소용 조성물은 ADH와 ALDH의 활성을 촉진시켜서 알코올과 아세트알데히드의 분해를 촉진하는 효과가 있으므로 숙취해소용 식품, 음료로서 유용하게 사용될 수 있다.The present invention relates to a hangover relief composition containing a crude herbal extract extract, the composition for hangover elimination of the present invention containing an extract of dried, soft, and strip or as an active ingredient And it promotes the activity of ALDH and has the effect of promoting the decomposition of alcohol and acetaldehyde, so can be useful as a hangover food, beverage.
마름, 연자육, 지구자, 갈화, 숙취해소 Dried, lotus root, earthly, brownish, hangover
Description
본 발명은 마름, 연자육 및 지구자의 추출물 또는 마름, 연자육, 지구자 및 갈화의 추출물을 유효성분으로 함유하는 숙취해소용 조성물에 관한 것이다. The present invention relates to a hangover relief composition containing as an active ingredient extracts of dried, soft, and earth or dried, soft, earth, and brown.
음주문화의 특성으로 나타나는 과음과 빈번한 음주로 인해 많은 사람들이 숙취를 제거할 수 있는 약물에 관심을 갖고 있다. 숙취는 두통이나 속쓰림 등으로 나타나는데, 이는, 알코올이 체내 대사과정 중 인체에 해로운 아세트알데히드로 전환되고, 이것이 뇌와 간을 포함한 소화기관에 유해하게 작용함으로써 나타나는 현상이다. Many people are interested in drugs that can get rid of hangovers because of heavy drinking and frequent drinking. Hangovers are often caused by headaches or heartburn, which are caused by alcohol being converted to acetaldehyde, which is harmful to the body during metabolic processes, which is harmful to the digestive system, including the brain and liver.
다른 식품과 달리 조직 내에 저장되지 못하는 알코올은 간에서 알코올 탈수소효소(alcohol dehydrogenase; ADH)의 촉매 작용에 의해 아세트알데히드로 산화되며, 다시 알데히드탈수소효소(aldehyde dehydrogenase; ALDH)의 촉매작용으로 아세트산과 수소로 된다(조재열 등, 한국식품과학회지, 29(1), 167-172, 1997). 형성된 아세트산의 90%는 직접 CO2와 H2O가 되며 약 10%는 TCA 사이클을 거쳐서 완전히 분해된다(조재열 등; Lieber C.S. et al., Grune amd Stration, 253, 1986). Unlike other foods, alcohol that can't be stored in tissues is oxidized to acetaldehyde by the catalytic action of alcohol dehydrogenase (ADH), and then to acetic acid and hydrogen by the catalytic action of aldehyde dehydrogenase (ALDH). (Jae-Yeol Cho et al., Korean Food Science Society, 29 (1), 167-172, 1997). 90% of the acetic acid formed is directly CO 2 and H 2 O and about 10% is completely degraded via the TCA cycle (Cho Jae-Hyeol et al . ; Lieber CS et al. , Grune amd Stration , 253, 1986).
또한, 숙취의 원인물질로 알려진 아세트알데히드는 간의 마이크로좀에서 시스테인과 글루타티온을 비롯한 황함유물질과 높은 친화력을 가지고, 혈장막의 지질분 변화를 유발하여 지방간 및 간괴사 등의 간 손상을 일으킨다고 알려져 있다(Kaufman N. et al., AM. A. Arch. Path, 70, 331, 1960). In addition, acetaldehyde, known as a cause of hangover, has a high affinity with sulfur-containing substances such as cysteine and glutathione in the liver microsomes, and is known to cause liver damage such as fatty liver and liver necrosis by inducing lipid changes in the plasma membrane. (Kaufman N. et al. , AM.A. Arch.Path , 70, 331, 1960).
알코올은 섭취량에 따라 신체에 여러 가지 영향을 미치는데 짧은 시간 내에 과량의 알코올 섭취는 알데히드의 축적과 함께 구토, 두통, 혈압저하, 빈맥 및 쇼크 등을 유발하고, 특히 간내 지질 산화나 소포체에서의 약물대사 등을 방해하며, 만성적인 섭취에는 적응성이 유도되어 알코올 및 약물의 대사가 증가하고 지단백질의 생성이 가속화됨으로써 간세포의 손상을 가져온다(Rosser B.G. et al., Gastroenterology, 108, 252, 1995). 이러한 유해현상은 아세트알데히드의 생성시에 발생하는 과산화 반응과 MEOS(Microsomal Ethanol Oxidizing System)의 촉매에 의해 형성된 과량의 NADH에 의한 간세포의 파괴, 간세포의 화학적 평형저해, 대사이상 및 미토콘드리아의 기능 저해에서 기인된다(Bunsel R.G. et al., Behav. Vrain Res. 1, 351, 1980). 이 같은 유해반응 및 유해물질은 간세포의 손상을 초래하여 젖산과 같은 피로물질의 축적을 유도하며 ALDH의 활성을 감소시키고 비타민의 활성화를 저해하여 혈중 비타민의 양을 감소시키고 심장의 근육단백질 합성도 억제한다. 더욱이 증가된 수소는 직접 또는 간접적으로 지방산의 합성에 관여하여 지방 질 등을 형성함으로써 지방간이라는 병리적 현상을 초래한다(Lieber C.S. et al., Nutr.Sci. Viaminol., 29, 509, 1983).Alcohol affects the body depending on the amount of intake.In a short time, excessive alcohol intake causes vomiting, headache, lowering blood pressure, tachycardia and shock, along with accumulation of aldehydes, especially in liver lipid oxidation or endoplasmic reticulum. It impedes metabolism, and chronic adaptation leads to adaptation, which increases the metabolism of alcohol and drugs and accelerates the production of lipoproteins, resulting in damage to liver cells (Rosser BG et al. , Gastroenterology , 108, 252, 1995). These harmful phenomena are caused by the destruction of hepatocytes by excessive NADH formed by the peroxidation reaction occurring during the production of acetaldehyde and the catalyst of MEOS (Microsomal Ethanol Oxidizing System), the chemical equilibrium of hepatocytes, metabolic abnormalities and the inhibition of mitochondrial function. (Bunsel RG et al. , Behav. Vrain Res. 1, 351, 1980). These harmful reactions and harmful substances cause hepatic cell damage, leading to the accumulation of fatigue substances such as lactic acid, reducing the activity of ALDH, inhibiting the activation of vitamins, reducing the amount of vitamins in the blood and inhibiting the synthesis of muscle protein in the heart. do. Moreover, increased hydrogen is directly or indirectly involved in the synthesis of fatty acids to form fats and the like, resulting in the pathological phenomenon of fatty liver (Lieber CS et al. , Nutr. Sci. Viaminol. , 29, 509, 1983).
한편, 최근 들어 알코올의 독성을 경감시키거나 독성의 발현을 저해할 수 있는 많은 물질에 대한 연구와 실험이 진행되고 있으며, 그 결과 천연식품이나 한약재료로부터 추출한 성분이나 인공제재를 함유한 다양한 건강보조식품이 이와 관련되어 개발되고 있다.On the other hand, research and experiments on a number of substances that can reduce the toxicity of alcohol or inhibit the expression of toxicity are in progress, and as a result, various health supplements containing ingredients or artificial ingredients extracted from natural foods or herbal ingredients Food is being developed in this regard.
하지만, 이와 같이 음주로 인한 숙취 또는 알코올의 독성에 기인한 해로운 영향을 해소하기 위해 생약 제재 또는 인공제재를 이용하여 제조된 드링크류가 다수 개발되어 판매되고 있으나 아직까지 만족할 만한 효과를 얻을 수 없는 실정이다.However, in order to solve the harmful effects caused by the hangover or alcohol toxicity caused by drinking, a large number of drinks manufactured using herbal or artificial preparations have been developed and sold. However, there are still no satisfactory effects. to be.
마름(Trapa japonica Flerov)은 마름과(Hydrocaryaceae)에 속하는 1년생 초본으로 물 속에서 자란다. 마름열매인 능실은 약 15%가 전분으로 구성되어 있으며, 이외에도 포도당, 단백질, 비타민 C, 비타민 B 등의 성분을 함유하고 약간 단 맛을 가지고 있다. Trapa japonica Flerov is an annual herb belonging to the Hydrocaryaceae, which grows in water. About 15% of the walnut fruit, which is a dried fruit, is composed of starch, and also contains components such as glucose, protein, vitamin C, and vitamin B, and has a slightly sweet taste.
연자육은 수련과의 연꽃(Nelumbo nucifera Gaertn.)의 성숙한 열매껍데기를 제거한 종자로서, 그 내부에 녹색 연심이 있으며, 냄새는 없고, 맛은 달면서 약간 떫다. 연자육의 성분은 다량의 전분과 단백질, 지방, 탄수화물, 칼슘, 인, 철 등이며 심기를 보양하고 콩팥 및 지라를 보호하고 장을 수렴하는 효능이 탁월하므로 만성설사와 만성이질, 허사 및 장출형 또는 대하증에도 좋은 효과를 나타낸다.The lotus root is a seed removed from the mature fruit shell of the lotus ( Nelumbo nucifera Gaertn.), Which has a green core inside, has no smell, and tastes slightly sweet. The components of lotus root meat are large amounts of starch and protein, fat, carbohydrates, calcium, phosphorus, iron, etc., and it is excellent for cultivating planting, protecting kidneys and spleen, and converging the intestines. It also has a good effect on macrophages.
지구자는 갈매나무과의 헛개나무(Hovenia dulcis Thunb.)의 과병을 가진 열매 또는 씨를 의미하는데, 납작한 원형으로 냄새가 조금 있고 맛은 쓰면서 떫다. 지구자는 열병으로 인한 번열, 구갈, 딸꾹질, 구토 등에 쓰며 이뇨를 돕고, 알코올중독으로 상한 간장을 치료한다. Earthling refers to the fruit or seed of the fruit of the buckthorn of Hovenia dulcis Thunb., Which is a flat round, slightly smelly and tastes bitter. Earthlings are used for fever, dry mouth, hiccups, vomiting, etc. to help diuresis and to cure soy liver with alcoholism.
갈화는 칡(Pueraria lobata (Willd.) Ohwi)의 꽃을 의미하는데, 과음으로 인한 두통, 발열, 갈증, 식욕부진, 복부팽만 및 구토증을 다스린다.Browning refers to the flowers of Pueraria lobata (Willd.) Ohwi, which controls headaches, fever, thirst, anorexia, bloating and vomiting caused by heavy drinking.
이에 본 발명자들은 마름, 연자육 및 지구자의 추출물 또는 마름, 연자육, 지구자 및 갈화의 추출물을 유효성분으로 함유하는 조성물이 숙취 해소에 탁월한 효과가 있음을 확인하여 본 발명을 완성하였다.Accordingly, the present inventors have completed the present invention by confirming that the composition containing the extract of dried, soft, and earth or the extract of dried, soft, earth, and browning as an active ingredient has an excellent effect on the hangover.
본 발명의 목적은 ADH와 ALDH의 활성을 촉진시켜서 알코올과 아세트알데히드의 분해를 촉진하는 효과를 나타내는 숙취해소용 생약 조성물을 제공하는 것이다. SUMMARY OF THE INVENTION An object of the present invention is to provide a hangover herb composition for promoting hangover activity of ADH and ALDH, which has an effect of promoting decomposition of alcohol and acetaldehyde.
상기 목적에 따라, 본 발명은 마름, 연자육 및 지구자의 추출물을 유효성분으로 함유하는 숙취해소용 조성물을 제공한다.In accordance with the above object, the present invention provides a hangover relief composition containing the extract of dried, soft and the earth as an active ingredient.
또한, 본 발명은 마름, 연자육, 지구자 및 갈화의 추출물을 유효성분으로 함유하는 숙취해소용 조성물을 제공한다.In another aspect, the present invention provides a hangover relief composition containing the extract of dried, lotus root, earth and browning as an active ingredient.
마름, 연자육 및 지구자의 추출물 또는 마름, 연자육, 지구자 및 갈화의 추출물을 유효성분으로 함유하는 본 발명의 숙취해소용 조성물은 ADH와 ALDH의 활성을 촉진시켜서 알코올과 아세트알데히드의 분해를 촉진하는 효과를 나타내므로 숙취해소용 식품 및 음료로서 유용하게 사용될 수 있다.Hangover-relieving composition of the present invention containing the extract of dried, softened and stripped or dried, softened, stripped and browned as an active ingredient to promote the decomposition of alcohol and acetaldehyde by promoting the activity of ADH and ALDH It can be usefully used as a food and beverage for hangover.
본 발명의 숙취해소용 조성물은 유효성분인 마름, 연자육 및 지구자의 추출물 또는 마름, 연자육, 지구자 및 갈화의 추출물을 전체 조성물의 0.01 내지 95 중 량%, 바람직하게는 1 내지 80 중량%의 양으로 포함한다.Hangover composition of the present invention is an active ingredient of the extract of dried, soft, and earth or the extract of dried, soft, earth, and browning of 0.01 to 95% by weight, preferably 1 to 80% by weight of the total composition Include as.
또한, 본 발명의 숙취해소용 조성물은 마름, 연자육 및 지구자의 추출 전 원료를 1.0~8.0 : 0.75~3.0 : 1의 중량비, 바람직하게는 2.0~7.0 : 1.0~2.0 : 1의 중량비로 추출한다.In addition, the hangover relief composition of the present invention extracts the raw material before extraction of dried, soft meat and earth strips in a weight ratio of 1.0 to 8.0: 0.75 to 3.0: 1, preferably 2.0 to 7.0: 1.0 to 2.0: 1.
또한, 본 발명의 숙취해소용 조성물은 마름, 연자육, 지구자 및 갈화의 추출 전 원료를 1.3~16.0 : 0.7~6.0 : 0.6~4.0 : 1의 중량비, 바람직하게는 2.0~8.0 : 1.0~3.0 : 1.0~2.0 : 1의 중량비로 추출한다. 바람직한 중량비는 원료의 상태에 따라 달라질 수 있다.In addition, the hangover relief composition of the present invention is a weight ratio of 1.3 ~ 16.0: 0.7 ~ 6.0: 0.6 ~ 4.0: 1, preferably 2.0 ~ 8.0: 1.0 ~ 3.0: Extract at a weight ratio of 1.0 to 2.0: 1. Preferred weight ratios may vary depending on the condition of the raw materials.
또한, 본 발명의 숙취해소용 조성물 중 마름은 외피를 포함하는 것이 바람직하다.In addition, it is preferable that the dryness of the hangover relief composition of this invention contains an outer shell.
또한, 본 발명의 숙취해소용 조성물은 숙취해소에 효과가 있다고 당업계에 알려져 있는 다른 생약의 추출물을 추가로 포함할 수 있다.In addition, the hangover composition of the present invention may further include extracts of other herbal medicine known in the art that is effective in relieving hangover.
본 발명의 숙취해소용 조성물에 함유되는 생약 추출물은 생약 자체를 그대로 또는 세절 또는 분말 형태로 하여, 통상적인 추출 방법, 예를 들면 열수 추출 또는 유기용매로 추출하여 제조할 수 있다. 또한 본 발명의 숙취해소용 조성물은 생약 추출물로서 상기 추출물을 건조시켜 얻어진 건조분말 또는 시판되는 생약 추출물 분말의 혼합물을 포함할 수도 있다. 추출물 제조시에 생약은 건조한 것, 건조하지 않은 것 또는 이들을 서로 혼합한 상태의 것을 사용할 수 있다. The herbal extract contained in the hangover relief composition of the present invention may be prepared by extracting the herbal medicine itself as it is or in the form of a fine or powdered form, using a conventional extraction method, for example, hot water extraction or an organic solvent. In addition, the hangover composition of the present invention may comprise a mixture of a dry powder or a commercial herbal extract powder obtained by drying the extract as a herbal extract. At the time of extract preparation, the herbal medicines may be dried, not dried, or mixed with each other.
본 발명의 숙취해소용 조성물에 함유되는 생약 추출물은, 예를 들어, 건조시킨 생약을 세절한 후, 약 3배 내지 1000배 중량의 물, 유기용매 또는 이들의 혼합 용매로 실온 내지 60~130℃의 추출온도에서 약 1시간 내지 10일 동안 열수추출, 냉침추출, 초고압 추출 또는 환류냉각 추출 등의 추출방법에 의하여 1회 내지 5회 반복하여 추출한 후, 추출물을 여과, 감압농축 또는 동결건조하여 제조될 수 있다. 상기 유기용매로는 C1-4 저급알콜, 에틸아세테이트, 클로로포름, 헥산, 디클로로메탄 등을 예시할 수 있다.The herbal extracts contained in the hangover relief composition of the present invention may be, for example, chopped dried herbal medicines, and then stored at room temperature to 60 to 130 ° C. with water, an organic solvent or a mixed solvent of about 3 to 1000 times the weight. After extracting repeatedly 1 to 5 times by the extraction method such as hot water extraction, cold sedimentation, ultrahigh pressure extraction or reflux cooling extraction for about 1 hour to 10 days at the extraction temperature of the extract, the extract is filtered, concentrated under reduced pressure or lyophilized Can be. Examples of the organic solvent may include C 1-4 lower alcohol, ethyl acetate, chloroform, hexane, dichloromethane, and the like.
본 발명의 생약 추출물은, 본 발명의 시험예에서 확인된 바와 같이, ADH 활성 촉진 효과 및 ALDH 활성 촉진 효과를 나타내고, 래트를 이용한 생체내 실험에서 알코올 및 아세트알데히드 분해 촉진 효과를 나타낸다. 따라서, 상기 생약 추출물을 유효성분으로 함유하는 본 발명의 숙취해소용 조성물은 우수한 숙취해소 효과를 나타낸다.The herbal extract of the present invention, as confirmed in the test example of the present invention, exhibits the effect of promoting ADH activity and promoting ALDH activity, and shows the effect of promoting alcohol and acetaldehyde degradation in an in vivo experiment using rats. Therefore, the hangover relief composition of the present invention containing the herbal extract as an active ingredient shows an excellent hangover relief effect.
본 발명은 또한 상기 생약 추출물을 유효성분으로 함유하는 숙취해소용 건강 증진 식품을 제공한다. The present invention also provides a hangover relief health promoting food containing the herbal extract as an active ingredient.
본 발명의 건강 증진 식품은 상기 생약 추출물을 전체 식품의 0.01 내지 95 중량%, 바람직하게는 1 내지 80 중량%의 양으로 포함한다.The health promoting food of the present invention comprises the herbal extract in an amount of 0.01 to 95% by weight, preferably 1 to 80% by weight of the total food.
또한, 본 발명의 건강 증진 식품에 포함되는 생약 추출물의 중량비 및 제조 방법은 상기한 바와 같다.In addition, the weight ratio and manufacturing method of the herbal extracts contained in the health promoting food of the present invention is as described above.
본 발명의 건강 증진 식품은 분말, 과립, 정제, 캡슐 또는 음료 형태일 수 있으며, 건강 증진을 위한 기타의 천연 또는 합성 물질 및 제품화를 위한 첨가물 등을 추가로 포함할 수 있다.The health promoting food of the present invention may be in the form of powder, granules, tablets, capsules or beverages, and may further include other natural or synthetic substances for health promotion and additives for commercialization.
본 발명의 건강 증진 식품으로는, 예를 들어 각종 식품류, 음료류, 껌류, 비타민 복합제, 건강보조식품류 등이 있다.Examples of the health promoting food of the present invention include various foods, beverages, gums, vitamin complexes, and health supplements.
본 발명은 또한 상기 생약 추출물을 유효성분으로 함유하는 숙취해소용 음료를 제공한다. The present invention also provides a hangover drink containing the herbal extract as an active ingredient.
본 발명의 음료는 상기 생약 추출물을 전체 조성물의 0.01 내지 95 중량%, 바람직하게는 1 내지 80 중량%의 양으로 포함한다.The beverage of the present invention comprises the herbal extract in an amount of 0.01 to 95% by weight, preferably 1 to 80% by weight of the total composition.
또한, 본 발명의 음료에 포함되는 생약들의 중량비 및 제조 방법은 상기한 바와 같다.In addition, the weight ratio and manufacturing method of the herbal medicines included in the beverage of the present invention are as described above.
본 발명의 건강음료는 100㎖를 기준으로 상기 생약 추출물을 1 내지 100g의 비율로 함유할 수 있다. 또한, 지시된 비율로 필수 성분으로서 상기 추출물을 함유한다면 액체성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등 디사카라이드, 예를 들어 말토스, 슈크로스 등 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 크실리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어, 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다. Health drink of the present invention may contain the herbal extract in the ratio of 1 to 100g based on 100ml. In addition, if the extract contains the extract as an essential ingredient in the indicated ratio, there is no particular limitation on the liquid component, and may contain various flavors or natural carbohydrates, etc. as additional ingredients, as in general beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and other disaccharides such as maltose, sucrose and the like, and conventional sugars such as polysaccharides such as dextrin, cyclodextrin, And sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.
상기 외에 본 발명의 숙취해소용 건강 증진 식품은 여러가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진 제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 음료 형태의 본 발명의 건강 증진 식품은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 본 발명의 건강 증진 식품 100 중량부 당 1 내지 약 90 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the health-enhancing food for hangover of the present invention includes various nutrients, vitamins, minerals (electrolytes), synthetic flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof. , Alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks and the like. In addition, the health promoting food of the present invention in the form of a beverage may contain pulp for the production of natural fruit juice and fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The proportion of such additives is generally selected from the range of 1 to about 90 parts by weight per 100 parts by weight of the health promoting food of the present invention.
이하, 하기 실시예 및 시험예에 의하여 본 발명을 더욱 상세하게 설명하고자 한다. 단, 하기 실시예 및 시험예는 본 발명을 예시하기 위한 것일 뿐 본 발명의 범위가 이들만으로 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following examples and test examples. However, the following Examples and Test Examples are only for illustrating the present invention, but the scope of the present invention is not limited thereto.
실시예 1: 추출액의 제조Example 1 Preparation of Extract
마름, 연자육, 지구자 및 갈화 각각의 추출액은 아래 표 1에 기재된 바와 같이, 이들 각각에 물을 가한 후 열수 침출을 통해 수득하였다. 천연물 원료는 모두 건조된 상태의 것을 사용하였다. Extracts of each of dried, soft, earthy and browned powders were obtained through hydrothermal leaching after adding water to each of them, as shown in Table 1 below. Natural raw materials were all used in a dried state.
실시예 2: 숙취해소용 조성물의 제조Example 2: Preparation of Hangover Composition
마름, 연자육 및 지구자를 마름(외피 포함) 70g/L, 연자육 15g/L 및 지구자(과병 포함) 15g/L의 비율로 혼합한 후, 6시간 열수 침출하여 혼합 조성물 A를 수득하였다. 그리고, 마름, 연자육, 지구자 및 갈화를 마름 25g/L, 연자육 15g/L, 지구자(과병 포함) 15g/L 및 갈화 10g/L의 비율로 혼합한 후, 6시간 열수 침출하여 혼합 조성물 B를 수득하였다.After drying at a rate of 70 g / L dry (including skin), 15 g / L soft skin, and 15 g / L soft earth (including fruit), dried, hydrothermal leaching for 6 hours to obtain a mixed composition A. And, after mixing the dry, softened, earthed and browned at the rate of dry 25g / L, softened meat 15g / L, earthen (including fruit) 15g / L and browned 10g / L, and mixed for 6 hours by hydrothermal leaching Obtained.
시험예 1: ADH 활성 측정 방법Test Example 1: Method for Measuring ADH Activity
흡광도 340nm에서 NADH의 생성속도를 지표로 하는 Blandino의 방법(Blandino, A. et al., Biotech. Letts., 19(7), 65118, 1997)을 변형한 건강기능식품의 기능성 시험 가이드(Ⅰ)(식품의약품 안전청, 2004년 3월)에 수록된 방법을 근간으로 효소원을 효모 ADH로 변경하여 실험하였다. Functional Test Guide of Functional Foods Modified by Blandino's Method (Blandino, A. et al., Biotech. Letts., 19 (7), 65118, 1997) as the Index of NADH Production at Absorbance 340nm (Ⅰ) Based on the method described in the Korea Food and Drug Administration, March 2004, the enzyme source was changed to yeast ADH.
시험예 2: ALDH 활성 측정 방법Test Example 2: ALDH Activity Measurement Method
흡광도 340nm에서 NADH의 생성속도를 지표로 하는 Bostian의 방법(Bostian. et al., Biochem. J., 173, 787, 1978)을 변형한 건강기능식품의 기능성 시험 가이드(Ⅰ)(식품의약품 안전청, 2004년 3월)에 수록된 방법을 사용하였다.Functional test guide (I) of health functional foods modified from Bostian's method (Bostian. Et al., Biochem. J. , 173, 787, 1978) as an indicator of the rate of NADH production at absorbance of 340 nm (Food and Drug Administration, The method described in March 2004) was used.
시험예 3: 마름 추출액의 ADH 및 ALDH 활성 촉진 효과Test Example 3 ADH and ALDH Activity Promoting Effect of Dried Extract
마름 추출액의 ADH 및 ALDH 활성 촉진 효과를 알아보기 위하여, 상기 시험예 1 및 2의 방법을 이용하여 상기 실시예 1의 마름 추출액(외피 포함 추출, 60g/L)의 ADH 및 ALDH 활성 증가율을 측정하여 각각 표 2 및 3에 나타내었다.In order to examine the effect of promoting ADH and ALDH activity of the dried extract, by measuring the increase rate of ADH and ALDH activity of the dried extract of Example 1 (external coating, 60g / L) using the method of Test Examples 1 and 2 Tables 2 and 3, respectively, are shown.
그 결과, 외피를 포함한 마름은 ADH 및 ALDH 활성을 증가시키는 효과를 나타내었다.As a result, the dryness including the skin showed the effect of increasing the ADH and ALDH activity.
시험예 4: 연자육 추출액의 ALDH 활성 촉진 효과Experimental Example 4: ALDH Activity Promoting Effect of Lotus Root Extract
연자육 추출액의 ALDH 활성 촉진 효과를 알아보기 위하여, 상기 시험예 2의 방법을 이용하여 상기 실시예 1의 연자육 추출액(22g/L)의 ALDH 활성 증가율을 측정하여 표 4에 나타내었다.In order to determine the effect of promoting the ALDH activity of the extract of the soft lotus, the increase rate of ALDH activity of the soft extract of Example 1 (22g / L) of Example 1 using the method of Test Example 2 is shown in Table 4.
그 결과, 연자육의 추출액은 ALDH 활성을 증가시키는 효과를 나타내었다. As a result, the extract of lotus root meat showed an effect of increasing ALDH activity.
시험예 5: 지구자 추출액의 ADH 및 ALDH 활성 촉진 효과Test Example 5: ADH and ALDH activity promoting effect of the extract
지구자 추출액의 ADH 및 ALDH 활성 촉진 효과를 알아보기 위하여, 상기 시험예 1 및 2의 방법을 이용하여 상기 실시예 1의 지구자 추출액(34g/L)을 희석 후 ADH 및 ALDH 활성 증가율을 측정하여 각각 표 5 및 6에 나타내었다.In order to determine the effect of promoting ADH and ALDH activity of the extract extract, after diluting the extract (34g / L) of Example 1 using the method of Test Examples 1 and 2 by measuring the rate of ADH and ALDH activity increase Tables 5 and 6 show, respectively.
그 결과, 지구자의 추출액은 ADH 및 ALDH 활성을 증가시키는 효과를 나타내었다. As a result, the extract of the earth showed an effect of increasing the ADH and ALDH activity.
시험예 6: 갈화 추출액의 ADH 및 ALDH 활성 촉진 효과Test Example 6 Effect of Promoting ADH and ALDH Activity of Gall Powder Extract
갈화 추출액의 ADH 및 ALDH 활성 촉진 효과를 알아보기 위하여, 상기 시험예 1 및 2의 방법을 이용하여 상기 실시예 1의 갈화 추출액(50g/L)을 희석 후 ADH 및 ALDH 활성 증가율을 측정하여 각각 표 7 및 8에 나타내었다.In order to determine the effect of promoting the ADH and ALDH activity of the galvanized extract, by diluting the galvanized extract of Example 1 (50g / L) using the method of Test Examples 1 and 2, respectively, the rate of increase in ADH and ALDH activity was measured. 7 and 8 are shown.
그 결과, 갈화의 추출액은 ADH 및 ALDH 활성을 증가시키는 효과를 나타내었다. As a result, the extract of browning showed an effect of increasing ADH and ALDH activity.
시험예 7: 숙취해소용 조성물의 ADH 활성 촉진 효과Experimental Example 7: ADH activity promoting effect of the hangover relief composition
숙취해소용 조성물의 ADH 활성 촉진 효과를 알아보기 위하여, 상기 시험예 1의 방법을 이용하여 시판 숙취음료 및 상기 실시예 2의 숙취해소용 조성물 A 및 B의 ADH 활성 증가율을 측정하여 각각 표 9 및 10에 나타내었다.In order to determine the effect of promoting the ADH activity of the hangover relief composition, by using the method of Test Example 1, the growth rate of ADH activity of the hangover drink and the hangover composition A and B of Example 2 were measured, respectively, to Table 9 and 10 is shown.
그 결과, 실시예 2의 조성물 A는 비교적 높은 ADH 활성 촉진 효과를 나타내었고, 조성물 B는 시판제품 이상의 ADH 활성 촉진 효과를 나타내었다.As a result, the composition A of Example 2 exhibited a relatively high ADH activity promoting effect, composition B showed a more than the commercially available ADH activity promoting effect.
시험예 8: 숙취해소용 조성물의 ALDH 활성 촉진 효과Experimental Example 8: ALDH activity promoting effect of the hangover relief composition
숙취해소용 조성물의 ALDH 활성 촉진 효과를 알아보기 위하여, 상기 시험예 2의 방법을 이용하여 숙취음료 시판제품(컨디션) 및 상기 실시예 2의 숙취해소용 조성물 A 및 B의 ALDH 활성 증가율을 측정하여 각각 표 11 및 12에 나타내었다.In order to investigate the ALDH activity promoting effect of the hangover relief composition, by using the method of Test Example 2 to measure the growth rate of the ALDH activity of the hangover beverage commercial products (condition) and the hangover composition A and B of Example 2 Tables 11 and 12, respectively, are shown.
그 결과, 실시예 2의 조성물 A 및 B 모두 시판제품보다 높은 ALDH 활성 촉진 효과를 나타내었다.As a result, both compositions A and B of Example 2 exhibited higher ALDH activity promoting effects than commercial products.
시험예 9: 숙취해소용 조성물의 알코올 및 아세트알데히드 분해 촉진 효과의 Test Example 9 Effect of Alcohol and Acetaldehyde Degradation Promoting Effect of Hangover Relief Composition in vivoin vivo 실험 방법 Experiment method
숙취해소용 조성물의 알코올 및 아세트알데히드 분해 촉진 효과를 알아보기 위하여 in vivo 실험을 실시하였다. 9개군(시료 A, B, C의 알코올 투여전 샘플을 주입한 군과 알코올 투여 후 샘플을 투여한 군 및 시료 D, E, 대조군을 합함) 69마리(시료 A, B, C, D, E는 전처리, 후처리 각각 6마리씩, 대조군은 9마리)의 래트(Sprague Dawley rat, 수컷, 각 체중 215~225g, 7주령)를 실험 전 18시간 동안 절식시킨 후에 시료 A, B, C, D 및 E(표 13)를 40% 에탄올을 8.4 ml/kg로 경구 투여하기 전 또는 후에 투여하였다. 시료 투여량 및 투여 시기는 표 14에 나타내었다. 표 14에서 전처리는 알코올 투여 30분 전에 시료를 투여한 것을 의미하고, 후처리는 알코올 투여 30분 후에 시료를 투여한 것을 의미한다. In vivo experiments were conducted to determine the effects of alcohol and acetaldehyde degradation on the hangover relief composition. 69 groups of 9 groups (Sample A, B, C, pre-alcohol-injected group, alcohol-administered sample and sample D, E, control group) 69 (Samples A, B, C, D, E (Sprague Dawley rat, male, 215-225 g each, 7 weeks old) were fasted for 18 hours before the experiment, and the samples A, B, C, D and E (Table 13) was administered before or after oral administration of 40 ml ethanol at 8.4 ml / kg. Sample dosages and dosing periods are shown in Table 14. In Table 14, pretreatment means that the sample is administered 30 minutes before alcohol administration, and post-treatment means that the sample is administered 30 minutes after alcohol administration.
이후, 전처리의 경우 알코올 투여 후 30분, 150분, 270분 후에, 후처리의 경우 시료 투여 후 30분, 150분, 270분 후에, 부분 채혈로 심장 채혈을 하였다. 그 후, 3,000 rpm, 20 min의 원심분리로 혈청을 분리하여 키트 검사(Ethanol & Acetaldehyde Kit(r-Bioform, Roche))를 통해서 혈중 알코올 농도 및 아세트알데히드 농도를 측정하였다. 측정 방법은 제조사의 프로토콜을 사용하였다.Thereafter, 30 minutes, 150 minutes and 270 minutes after the administration of alcohol in the pretreatment, 30 minutes, 150 minutes and 270 minutes after the administration of the sample in the post-treatment, the blood was collected by partial blood collection. Thereafter, serum was separated by centrifugation at 3,000 rpm and 20 min, and blood alcohol concentration and acetaldehyde concentration were measured through a kit test (Ethanol & Acetaldehyde Kit ( r- Bioform, Roche)). The measurement method used the manufacturer's protocol.
시험예 10: 숙취해소용 조성물의 알코올 분해 촉진의 Test Example 10: Promoting Alcohol Degradation of Hangover Relief Composition in vivoin vivo 효과 effect
상기 시험예 9에서 측정한 각 시료의 혈중 알코올 농도의 감소 효과를 표 15 내지 18에 나타내었다.Table 15 to 18 shows the effect of reducing the blood alcohol concentration of each sample measured in Test Example 9.
*AUC(Area Under Curve) 분석: 혈중 약물 농도-시간 곡선하 면적으로서 약물의 생체 흡수율의 정도를 의미하며 전신순환에 도달한 활성약물의 총량을 반영한다.AUC (Area Under Curve) analysis: Area under the drug concentration-time curve in blood, indicating the degree of bioabsorption of the drug and reflecting the total amount of active drug that has reached systemic circulation.
상기 표 18에서, 대조군과 대비하여 통계적 유의성이 있을 때 +, 없을 때 -로 표시하였다(이하 동일).In Table 18, it was expressed as +, when there is no statistical significance compared to the control group-(same as below).
이와 같이, 혈중 알코올 농도를 통한 동물 실험 결과, 시료 C와 시료 E를 비교해 볼 때, 마름, 연자육, 지구자 및 갈화 추출액은 시판제품에 비해서 뛰어난 알코올 분해 촉진 효과를 나타내었다.As a result of animal experiments using blood alcohol concentration, when comparing sample C and sample E, dried, soft meat, earth and browning extract showed an excellent alcohol degradation promoting effect compared to commercial products.
시험예 11: 숙취해소용 조성물의 아세트알데히드 분해 촉진의 Experimental Example 11: Accelerating Acetaldehyde Degradation of the Hangover Relief Composition in vivoin vivo 효과 effect
상기 시험예 9에서 측정한 각 시료의 혈중 아세트알데히드 농도의 감소 효과를 표 19 내지 22에 나타내었다.Table 19 to 22 show the effect of reducing the acetaldehyde concentration in blood of each sample measured in Test Example 9.
이와 같이, 혈중 아세트알데히드 농도를 통한 동물 실험 결과, 시료 C와 시료 D 및 E를 비교해 볼 때, 마름, 연자육, 지구자 및 갈화 추출액은 시판제품보다 뛰어난 아세트알데히드 분해 촉진 효과를 나타내었다.As a result of animal experiments using blood acetaldehyde concentration, when comparing samples C and D and E, dried, soft meat, earth and browned extracts showed better acetaldehyde degradation promoting effects than commercial products.
이하, 본 발명의 숙취 해소용 조성물을 위한 제제예를 예시한다.Hereinafter, the formulation example for the hangover composition of this invention is illustrated.
제제예 1. 농축액제의 제조Formulation Example 1 Preparation of Concentrate
실시예 2의 생약조성물 600 mg600 mg herbal composition of Example 2
올리고당 600 mgOligosaccharide 600 mg
배농축액 500 mgPear Concentrate 500 mg
혼합비타민 30 mgMixed Vitamin 30 mg
딸기향 적량 Strawberry flavor
정제수를 가하여 전체 30 ml로 맞추었다. 통상의 액제의 제조방법에 따라 상기의 성분을 혼합한 다음, 폴리에틸렌 재질의 포에 충전하고 멸균시켜 농축액제를 제조하였다. Purified water was added to make a total of 30 ml. The above components were mixed according to a conventional method for preparing a liquid, and then filled into a polyethylene cloth and sterilized to prepare a concentrate.
제제예 2. 건강 증진 식품의 제조Formulation Example 2 Preparation of Health Promoting Food
실시예 2의 생약조성물 150 mg150 mg of the herbal composition of Example 2
유당 120 mgLactose 120 mg
유청칼슘 30 mgWhey Calcium 30 mg
비타민 D3 30 mgVitamin D3 30 mg
비타민 C 20 mgVitamin C 20 mg
녹차추출물분말 적량Green Tea Extract Powder
판토텐산칼슘 적량Calcium pantothenate
L-시스틴 적량L-cystine titrant
자일리톨 적량Xylitol Proper
스테아린산마그네슘 적량Magnesium stearate appropriate amount
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강 식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강증진 식품을 제조하였다.The composition ratio of the above-mentioned vitamin and mineral mixtures is a composition suitable for a relatively healthy food in a preferred embodiment, but the composition ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method. Granules were prepared, and health promoting foods were prepared according to conventional methods.
제제예 3. 음료의 제조Formulation Example 3 Preparation of Beverage
구연산 0.25 g0.25 g citric acid
과당 35 gFructose 35 g
포도주스 60 g60 g of grape juice
레몬주스 0.2 g0.2 g of lemon juice
실시예 2의 생약 조성물을 가하여 전체 1000 ㎖1000 ml total by adding the herbal composition of Example 2
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 여과하여 100㎖ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관하였다.The above ingredients were mixed according to the conventional healthy beverage preparation method, filtered and obtained in a 100 ml container, sealed and sterilized, and then refrigerated.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080135697A KR101072897B1 (en) | 2008-12-29 | 2008-12-29 | COMPOSITION FOR ALLEVIATING A HANGOVER COMPRISING AN EXTRACT OF Trapa japonica Flerov |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080135697A KR101072897B1 (en) | 2008-12-29 | 2008-12-29 | COMPOSITION FOR ALLEVIATING A HANGOVER COMPRISING AN EXTRACT OF Trapa japonica Flerov |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100077678A KR20100077678A (en) | 2010-07-08 |
KR101072897B1 true KR101072897B1 (en) | 2011-10-17 |
Family
ID=42639000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080135697A KR101072897B1 (en) | 2008-12-29 | 2008-12-29 | COMPOSITION FOR ALLEVIATING A HANGOVER COMPRISING AN EXTRACT OF Trapa japonica Flerov |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101072897B1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102349950B (en) * | 2011-10-20 | 2013-05-22 | 中山火炬职业技术学院 | Food, health product or pharmaceutical composition as well as preparation method and application thereof |
KR101247927B1 (en) * | 2012-07-16 | 2013-03-26 | 보령제약 주식회사 | Composition for prevention or relief of alcoholic hangover |
JP6241625B2 (en) * | 2014-01-21 | 2017-12-06 | 株式会社東洋新薬 | Container-packed beverage |
KR101820676B1 (en) * | 2017-07-20 | 2018-01-23 | 콜마비앤에이치 주식회사 | Composition for improving hangover comprising trapa japonica extract and curcumin as an effective ingredient |
KR102468614B1 (en) | 2020-08-03 | 2022-11-17 | 변한섭 | Cultivation method of cordyceps militaris hypha and hangover food therewith |
-
2008
- 2008-12-29 KR KR1020080135697A patent/KR101072897B1/en active IP Right Grant
Non-Patent Citations (1)
Title |
---|
아주대학교 대학원 이학석사학위논문 '수생식물 통기조직 특성 및 형성기작 연구' (2005.12.)* |
Also Published As
Publication number | Publication date |
---|---|
KR20100077678A (en) | 2010-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101072897B1 (en) | COMPOSITION FOR ALLEVIATING A HANGOVER COMPRISING AN EXTRACT OF Trapa japonica Flerov | |
KR101436784B1 (en) | Stick gel composition of red ginseng reduced bitterness and improved intake and manufacturing method thereof | |
KR101054594B1 (en) | Liver Function Enhancer Composition | |
KR20100119150A (en) | Composition for alleviating a hangover comprising an extract of chestnut(castanea crenata) inner skin | |
KR100552398B1 (en) | An alcohol detoxification beverage comprising extract of horse bean | |
KR20060098283A (en) | Mixtures of antioxidand supplement for current or former smokers and manufacturing method therof | |
KR101461165B1 (en) | Hangover curing agent | |
KR20060135005A (en) | Agent improving moisture-retention function of skin | |
EP2322193A1 (en) | Xanthine oxidase inhibitor and uric acid production inhibitor | |
KR101024238B1 (en) | The manufacturing method of vinegar using mainly Gastrodia elata Blume, and its product | |
KR101482719B1 (en) | Composition comprising extracts of Pueraria lobata Ohwi's new vines, Pueraria lobata Ohwi's root and Sorbus commixta to relieve hangover and improve liver function | |
KR100793205B1 (en) | Health Supporting Foods for Improving Coronary Heart Diseases or Arteriosclerosis Containing an Extract of Chinese Herb as an Effective Ingredient | |
JP2010275288A (en) | Functional composition for preventing and improving hangover, food and food additive containing the same | |
WO2007120007A1 (en) | Extract of echinosophora koreensis removing hangover and having anti-oxidant activity | |
KR100608456B1 (en) | Composition comprising complex herb extract of Opuntia ficus indica, Alnus japonica, Pueraria lobata and Hovenia dulcis showing hangover alleviating activity | |
KR101210748B1 (en) | Composition comprising the extract of Acanthopanax sessiliflorus and green tea for treating or alleviating hangover syndrome | |
KR100789399B1 (en) | Health Beverage composition containing the extract of Laminaria sp. Gelidium sp. and Grateloupia sp. | |
KR20180102658A (en) | Detoxifying compositions for oral administration and methods for preparing the same | |
KR100872310B1 (en) | Functional composition for the cotinene metabolism improvement which is caused by with smoking and hangover removal, foods and food additive containing the same | |
WO2007120008A1 (en) | Extract of chrysanthemum zawadskii removing hangover activity | |
KR101274099B1 (en) | Composition for eliminating hangover comprising stems bud of Hovenia dulcis and Pueraria flos as effective component | |
KR20170084521A (en) | Fermented beverage with Chrysanthemum zawadskii leaves | |
WO2006033496A1 (en) | Functional composition for the prevention and alleviation of hangover | |
KR100690071B1 (en) | Functional composition for the prevention and improvement of hangover | |
KR102173223B1 (en) | Food composition containing extract of roasted codonopsis lanceolata or roasted platycodon grandiflorum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140829 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150909 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160902 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170904 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180829 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190905 Year of fee payment: 9 |